name: Chronic Myeloid Leukemia, BCR-ABL1 Positive
creation_date: '2026-01-26T02:55:13Z'
updated_date: '2026-02-16T21:20:00Z'
description: >-
  Chronic myeloid leukemia (CML), BCR-ABL1 positive, is a myeloproliferative neoplasm
  characterized by the Philadelphia chromosome, resulting from a reciprocal translocation
  t(9;22)(q34;q11) that creates the BCR-ABL1 fusion gene. The constitutively active
  BCR-ABL1 tyrosine kinase drives uncontrolled myeloid cell proliferation. CML is the
  paradigmatic example of oncogene addiction and targeted therapy success, with tyrosine
  kinase inhibitors transforming it from a fatal disease to a manageable chronic condition.
  This entry covers BCR-ABL1 positive CML, which represents approximately 95% of all CML cases.
categories:
- Hematologic Malignancy
- Myeloproliferative Neoplasm
parents:
- myeloid leukemia
stages:
- name: Chronic Phase
  description: >-
    Initial indolent phase characterized by mature granulocyte expansion with
    less than 10% blasts in blood or bone marrow. Most patients are diagnosed
    in this phase and respond well to tyrosine kinase inhibitors.
- name: Accelerated Phase
  description: >-
    Transitional phase marked by increasing blast counts (10-19%), basophilia,
    thrombocytopenia or thrombocytosis, and additional cytogenetic abnormalities.
    Indicates disease progression and decreased TKI responsiveness.
- name: Blast Crisis
  description: >-
    Terminal phase resembling acute leukemia with 20% or more blasts in blood
    or bone marrow. May be myeloid or lymphoid lineage. Poor prognosis with
    limited treatment options.
  evidence:
  - reference: PMID:11423618
    supports: PARTIAL
    snippet: "Clinical studies with the Abl tyrosine kinase inhibitor STI-571 in chronic myeloid leukemia demonstrate that many patients with advanced stage disease respond initially but then relapse."
    explanation: This paper demonstrates that advanced phase CML (blast crisis) has poor outcomes even with TKI therapy, reflecting disease progression.
pathophysiology:
- name: BCR-ABL1 Fusion Oncogene Formation
  description: >-
    The t(9;22)(q34;q11) translocation juxtaposes the ABL1 tyrosine kinase gene
    on chromosome 9 with the BCR gene on chromosome 22, creating the Philadelphia
    chromosome. The resulting BCR-ABL1 fusion protein has constitutive tyrosine
    kinase activity independent of normal regulatory mechanisms.
  cell_types:
  - preferred_term: hematopoietic stem cell
    term:
      id: CL:0000037
      label: hematopoietic stem cell
  biological_processes:
  - preferred_term: protein phosphorylation
    term:
      id: GO:0006468
      label: protein phosphorylation
  gene_products:
  - preferred_term: BCR-ABL1 fusion protein
    term:
      id: NCIT:C16325
      label: BCR/ABL1 Fusion Protein
  downstream:
  - target: Constitutive Tyrosine Kinase Activation
    description: The BCR-ABL1 fusion protein exhibits ligand-independent kinase activity
  evidence:
  - reference: PMID:11287972
    supports: SUPPORT
    snippet: "BCR-ABL is a constitutively activated tyrosine kinase that causes chronic myeloid leukemia (CML). Since tyrosine kinase activity is essential to the transforming function of BCR-ABL, an inhibitor of the kinase could be an effective treatment for CML."
    explanation: This landmark paper establishes that BCR-ABL is a constitutively activated tyrosine kinase that causes CML, directly supporting the pathophysiology description.
- name: Constitutive Tyrosine Kinase Activation
  description: >-
    The BCR-ABL1 fusion protein exhibits constitutive tyrosine kinase activity,
    bypassing normal growth factor regulation. This activates multiple downstream
    signaling cascades including RAS-MAPK, PI3K-AKT, and JAK-STAT pathways,
    promoting cell proliferation and survival.
  cell_types:
  - preferred_term: myeloid cell
    term:
      id: CL:0000763
      label: myeloid cell
  biological_processes:
  - preferred_term: protein tyrosine kinase activity
    modifier: INCREASED
    term:
      id: GO:0004713
      label: protein tyrosine kinase activity
  - preferred_term: signal transduction
    modifier: INCREASED
    term:
      id: GO:0007165
      label: signal transduction
  downstream:
  - target: RAS-MAPK Pathway Hyperactivation
    description: BCR-ABL1 activates RAS via GRB2/SOS, driving the MAPK proliferative cascade
  - target: PI3K-AKT Pathway Activation
    description: BCR-ABL1 activates PI3K via direct binding and adaptor proteins
  - target: JAK-STAT Pathway Activation
    description: BCR-ABL1 activates JAK-STAT signaling independent of cytokine receptors
  - target: Reactive Oxygen Species Generation
    description: Constitutive kinase activity increases mitochondrial ROS production
- name: RAS-MAPK Pathway Hyperactivation
  description: >-
    BCR-ABL1 activates the RAS-MAPK signaling cascade through GRB2/SOS adaptor
    proteins. Constitutive MAPK pathway activation drives uncontrolled myeloid
    progenitor proliferation by upregulating cell cycle progression genes.
  biological_processes:
  - preferred_term: MAPK cascade
    modifier: INCREASED
    term:
      id: GO:0000165
      label: MAPK cascade
  downstream:
  - target: Uncontrolled Myeloid Proliferation
    description: Hyperactive MAPK signaling drives excessive myeloid progenitor expansion
- name: PI3K-AKT Pathway Activation
  description: >-
    BCR-ABL1 activates the PI3K-AKT survival pathway through direct phosphorylation
    and adaptor protein recruitment. AKT phosphorylates and inactivates pro-apoptotic
    proteins (BAD, FOXO3a), upregulates BCL2 family anti-apoptotic members, and
    promotes cell survival.
  biological_processes:
  - preferred_term: PI3K-AKT signaling
    modifier: INCREASED
    term:
      id: GO:0043491
      label: protein kinase B signaling
  downstream:
  - target: Apoptosis Resistance
    description: AKT-mediated inactivation of pro-apoptotic factors promotes leukemic cell survival
- name: JAK-STAT Pathway Activation
  description: >-
    BCR-ABL1 activates JAK-STAT signaling independently of cytokine receptor
    engagement. STAT5 activation drives expression of proliferative and
    anti-apoptotic target genes, contributing to cytokine-independent growth
    of leukemic cells.
  biological_processes:
  - preferred_term: JAK-STAT signaling
    modifier: INCREASED
    term:
      id: GO:0007259
      label: receptor signaling pathway via JAK-STAT
  downstream:
  - target: Uncontrolled Myeloid Proliferation
    description: STAT5-driven transcriptional programs promote myeloid expansion
  - target: Apoptosis Resistance
    description: STAT5 upregulates BCL-XL and other anti-apoptotic factors
- name: Reactive Oxygen Species Generation
  description: >-
    BCR-ABL1 kinase activity increases mitochondrial reactive oxygen species (ROS)
    production. Chronic oxidative stress causes DNA double-strand breaks and
    impairs DNA repair fidelity, promoting acquisition of additional mutations
    and chromosomal abnormalities that drive disease progression.
  biological_processes:
  - preferred_term: reactive oxygen species biosynthetic process
    modifier: INCREASED
    term:
      id: GO:1903409
      label: reactive oxygen species biosynthetic process
  downstream:
  - target: Genomic Instability and Disease Progression
    description: ROS-induced DNA damage promotes acquisition of additional mutations driving blast crisis
- name: Uncontrolled Myeloid Proliferation
  description: >-
    BCR-ABL1 signaling drives excessive proliferation of myeloid progenitor cells,
    leading to marked expansion of the granulocytic lineage. The bone marrow becomes
    hypercellular with a massively expanded myeloid compartment.
  locations:
  - preferred_term: bone marrow
    term:
      id: UBERON:0002371
      label: bone marrow
  cell_types:
  - preferred_term: granulocyte
    term:
      id: CL:0000094
      label: granulocyte
  - preferred_term: myeloid progenitor cell
    term:
      id: CL:0000049
      label: common myeloid progenitor
  biological_processes:
  - preferred_term: myeloid cell homeostasis
    modifier: ABNORMAL
    term:
      id: GO:0002262
      label: myeloid cell homeostasis
- name: Apoptosis Resistance
  description: >-
    BCR-ABL1 activates anti-apoptotic pathways, particularly through PI3K-AKT
    signaling and upregulation of BCL2 family members. This confers resistance
    to programmed cell death, allowing accumulation of leukemic cells.
  biological_processes:
  - preferred_term: apoptotic process
    modifier: DECREASED
    term:
      id: GO:0006915
      label: apoptotic process
- name: Genomic Instability and Disease Progression
  description: >-
    BCR-ABL1 induces genomic instability through reactive oxygen species generation
    and impaired DNA repair. This promotes acquisition of additional mutations and
    chromosomal abnormalities, driving progression from chronic phase to blast crisis.
  biological_processes:
  - preferred_term: DNA repair
    modifier: DECREASED
    term:
      id: GO:0006281
      label: DNA repair
histopathology:
- name: Philadelphia Chromosome Positive Neoplasm
  finding_term:
    preferred_term: B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1
    term:
      id: NCIT:C36312
      label: B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1
  frequency: VERY_FREQUENT
  description: CML is defined by the presence of the Philadelphia chromosome (BCR-ABL1 fusion).
  evidence:
  - reference: PMID:33440869
    supports: SUPPORT
    snippet: "CML is defined by the presence of the Philadelphia (Ph)"
    explanation: Abstract defines CML by the Philadelphia chromosome.

phenotypes:
- category: Hematologic
  name: Leukocytosis
  frequency: VERY_FREQUENT
  diagnostic: true
  description: >-
    Marked elevation of white blood cell count, often exceeding 100,000/Î¼L at diagnosis.
    The differential shows increased granulocytes at all stages of maturation with
    a left shift to myelocytes and metamyelocytes.
  phenotype_term:
    preferred_term: Leukocytosis
    term:
      id: HP:0001974
      label: Increased total leukocyte count
- category: Hematologic
  name: Basophilia
  frequency: VERY_FREQUENT
  description: >-
    Elevated basophil count is characteristic of CML and may indicate disease
    acceleration when markedly increased.
  phenotype_term:
    preferred_term: Basophilia
    term:
      id: HP:0031807
      label: Increased total basophil count
- category: Hematologic
  name: Thrombocytosis
  frequency: FREQUENT
  description: >-
    Elevated platelet count occurs in many patients and may precede diagnosis.
    Extreme thrombocytosis can occur in some cases.
  phenotype_term:
    preferred_term: Thrombocytosis
    term:
      id: HP:0001894
      label: Thrombocytosis
- category: Hematologic
  name: Anemia
  frequency: FREQUENT
  description: >-
    Normochromic normocytic anemia develops due to bone marrow replacement by
    leukemic cells and ineffective erythropoiesis.
  phenotype_term:
    preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
- category: Constitutional
  name: Fatigue
  frequency: VERY_FREQUENT
  description: >-
    Profound fatigue is common, related to anemia and hypermetabolic state from
    rapid cell turnover.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Abdominal
  name: Splenomegaly
  frequency: VERY_FREQUENT
  diagnostic: true
  description: >-
    Massive splenomegaly from extramedullary hematopoiesis is characteristic.
    The spleen may extend to the pelvis and cause abdominal discomfort, early
    satiety, and left upper quadrant pain.
  phenotype_term:
    preferred_term: Splenomegaly
    term:
      id: HP:0001744
      label: Splenomegaly
- category: Abdominal
  name: Hepatomegaly
  frequency: FREQUENT
  description: >-
    Liver enlargement from extramedullary hematopoiesis and leukemic infiltration.
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
biochemical:
- name: Philadelphia Chromosome Detection
  notes: >-
    Cytogenetic analysis reveals t(9;22)(q34;q11) translocation creating the
    Philadelphia chromosome in 95% of CML cases.
- name: BCR-ABL1 Fusion Transcript
  biomarker_term:
    preferred_term: BCR-ABL1 fusion protein
    term:
      id: NCIT:C36715
      label: BCR-ABL1 Fusion Protein Expression
  notes: >-
    RT-PCR or FISH detection of BCR-ABL1 fusion is diagnostic and used for
    monitoring molecular response to therapy.
genetic:
- name: BCR-ABL1
  association: Somatic Fusion Oncogene
  notes: >-
    The t(9;22)(q34;q11) translocation creates a fusion between BCR on chromosome 22
    and ABL1 on chromosome 9. The resulting BCR-ABL1 fusion protein (p210 in CML)
    has constitutive tyrosine kinase activity that drives the disease.
  evidence:
  - reference: PMID:11287972
    supports: SUPPORT
    snippet: "BCR-ABL is a constitutively activated tyrosine kinase that causes chronic myeloid leukemia (CML)."
    explanation: Establishes that BCR-ABL fusion is the causative genetic lesion in CML.
  - reference: PMID:11423618
    supports: PARTIAL
    snippet: "These studies provide evidence that genetically complex cancers retain dependence on an initial oncogenic event."
    explanation: Confirms oncogene addiction - CML cells remain dependent on BCR-ABL signaling even in advanced disease.
treatments:
- name: Imatinib
  description: >-
    First-generation tyrosine kinase inhibitor that revolutionized CML treatment.
    Competitively inhibits BCR-ABL1 ATP binding, inducing molecular remission in
    most chronic phase patients. Standard first-line therapy with excellent long-term outcomes.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: imatinib
      term:
        id: CHEBI:45783
        label: imatinib
  evidence:
  - reference: PMID:11287972
    supports: SUPPORT
    snippet: "Complete hematologic responses were observed in 53 of 54 patients treated with daily doses of 300 mg or more and typically occurred in the first four weeks of therapy."
    explanation: The Druker phase 1 trial demonstrated that imatinib (STI571) induced complete hematologic responses in the vast majority of chronic phase CML patients.
  - reference: PMID:11287972
    supports: SUPPORT
    snippet: "Our results provide evidence of the essential role of BCR-ABL tyrosine kinase activity in CML and demonstrate the potential for the development of anticancer drugs based on the specific molecular abnormality present in a human cancer."
    explanation: This establishes that imatinib's efficacy proves the oncogene addiction paradigm in CML.
- name: Dasatinib
  description: >-
    Second-generation TKI with greater potency against BCR-ABL1 and activity against
    many imatinib-resistant mutations. Also inhibits SRC family kinases. Used for
    imatinib intolerance/resistance or as first-line therapy.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: dasatinib
      term:
        id: CHEBI:49375
        label: dasatinib
- name: Nilotinib
  description: >-
    Second-generation TKI designed for improved BCR-ABL1 binding. More selective
    than dasatinib with different side effect profile. Used for imatinib
    intolerance/resistance or first-line therapy.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: nilotinib
      term:
        id: CHEBI:52172
        label: nilotinib
- name: Ponatinib
  description: >-
    Third-generation TKI active against the T315I gatekeeper mutation that confers
    resistance to other TKIs. Reserved for patients with T315I mutation or failure
    of multiple prior TKIs due to cardiovascular risks.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: ponatinib
      term:
        id: CHEBI:78543
        label: ponatinib
  evidence:
  - reference: PMID:11423618
    supports: PARTIAL
    snippet: "In six of nine patients, resistance was associated with a single amino acid substitution in a threonine residue of the Abl kinase domain known to form a critical hydrogen bond with the drug. This substitution of threonine with isoleucine was sufficient to confer STI-571 resistance."
    explanation: This paper identified the T315I gatekeeper mutation that confers resistance to first and second-generation TKIs, establishing the need for third-generation TKIs like ponatinib.
- name: Allogeneic Stem Cell Transplantation
  description: >-
    Potentially curative option historically used as primary therapy before TKI era.
    Now reserved for patients failing multiple TKIs, those with T315I mutation
    without ponatinib access, or blast crisis. Significant morbidity and mortality risks.
  treatment_term:
    preferred_term: hematopoietic stem cell transplantation
    term:
      id: MAXO:0000747
      label: hematopoietic stem cell transplantation
disease_term:
  preferred_term: chronic myeloid leukemia
  term:
    id: MONDO:0011996
    label: chronic myelogenous leukemia, BCR-ABL1 positive

classifications:
  icdo_morphology:
    classification_value: Leukemia
  harrisons_chapter:
  - classification_value: cancer
  - classification_value: hematologic malignancy
